STALICLA successfully closed its initial Round of financing

STALICLA is proud to announce the successful closure of its initial round of financing at CHF 4M, committed from Biotech experienced investors. This round of funding will be used to advance STALICLA’s therapeutic towards clinical trial, as well as advancing ASD research using the innovative DEPI technology. With this investment, STALICLA is also looking to expand the team in order to support the ongoing research and future commercialization of identified therapeutics.

Back to News

Search for content on Stalicla...